Abstract: Human decidual placental mesenchymal stem cell having an increased expression level of decoy receptor 3 (DcR3), and a method for obtaining the human decidual placental mesenchymal stem cells having an increased expression level of DcR3 are provided, wherein human decidual placental mesenchymal stem cells are cultured in a culture dish containing a serum-free medium and the DcR3 expression of the human decidual placental mesenchymal stem cells are increased by stimulation of at least one inflammatory cytokine for 48 hours, and obtaining the human decidual placental mesenchymal stem cells having an increased expression level of DcR3, wherein the increased expression level of DcR3 is significantly higher than that of human decidual placental mesenchymal stem cells with the stimulation is higher than that of human decidual placental mesenchymal stem cells cultured without the stimulation of the at least one inflammatory cytokine.
Abstract: A nucleic acid molecule is uniquely designed and encodes an entire CRISPRi or CRISPRa system, while being sized for packaging within a single adeno-associated virus (AAV) vector. Examples of the nucleic acid molecule include about 4600 to 4700 base pairs. Examples of the nucleic acid molecule can include a nucleotide encoding a Cas polypeptide; a nucleotide encoding a repressor or an activator domain attached to the nucleotide encoding the Cas polypeptide via a linker; a first promoter operably connected to the nucleotide encoding the repressor or activator domain or the nucleotide encoding the Cas polypeptide; a nucleotide encoding an alpha-helical connecting the nucleotide encoding the Cas polypeptide to a nuclear localization signal (NLS); and a second promoter operably connected to a guide RNA (gRNA).
Abstract: A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
April 2, 2024
Assignee:
THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Inventors:
Frank Ho Pak Lau, Ian Hodgdon, Michael Cook
Abstract: Provided is a genetically modified non-human animal, in which at least one copy of the endogenous nucleotide sequence encoding Protein C in the genome of said the non-human animal has been replaced by a nucleotide sequence encoding human Protein C or a functional fragment or variant thereof. Also provided are vectors, cells, and methods for the production of such non-human animals. Further provided are methods of testing agents for their ability to alter to the level and/or functional activity of human protein C, for example, to test their potential therapeutic efficacy.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
February 13, 2024
Assignee:
Shanghai RAAS Blood Products Co., Ltd.
Inventors:
Jun Xu, Lu Cheng, Yeheng Liu, Jiawei Yi, Xuefeng Zhou
Abstract: The present invention provides a fluidic chip for cell culture use which can prevent a decrease in the activity of cultured cells in a preparation stage, and which makes it possible to observe a cultured cell tissue while detaching the cultured cell tissue from the fluidic chip.
Abstract: This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.
Abstract: The present invention relates to components, systems, and methods transcriptional modification (e.g., transcriptional activation) or methods of identifying transcriptional effectors based on Cas9-transcription effector fusion protein and gRNA sequence targeting.
Type:
Grant
Filed:
December 31, 2020
Date of Patent:
January 2, 2024
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: Provided is a method for more efficiently sorting out genetically modified cells. Specifically provided are a method for selecting a cell including a modified gene on a target locus in a genome, a method for producing a cell including a modified gene on a target locus in a genome, and an animal including a modified gene on a target locus in a genome, and a kit for selecting an animal including a modified gene on a target locus in a genome and cells including a modified gene on a target locus in a genome.
Type:
Grant
Filed:
January 4, 2022
Date of Patent:
December 19, 2023
Assignees:
LART BIO CO., LTD, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Goo Jang, Gyeongmin Gim, Dong Hyeok Kwon, Wonyou Lee
Abstract: A hanging drop device is provided in the present disclosure. The hanging drop device includes a hanging drop box and a negative pressure module. The hanging drop box includes a plate and a cover. The cover is coupled with the plate to jointly delimit a pressure chamber. The cover includes an upper surface and a bottom surface, a plurality of wells are recessed from the upper surface, and each of the wells is communicated with the pressure chamber through a hole. The negative pressure module is communicated with the pressure chamber. Each of the wells is for containing a liquid, the negative pressure module is for generating a negative pressure in the pressure chamber, so as to drive the liquid in each of the wells to pass through the hole, and the liquid forms a hanging drop hanging from the bottom surface of the cover.